TORONTO, Oct. 22 /CNW/ - Microbix Biosystems Inc. (TSX:MBX) has been
granted a patent by the U.S. Patent Office for its technology - VIRUSMAX(TM) -
which enables vaccine manufacturers to double the amount of influenza vaccine
they produce each year.
Microbix' discovery has enormous implications for protecting more people
during a pandemic. Patents are also being allowed in Canada, India and
Australia, and a number of other applications in major markets are currently
"We're delighted that we now have strong patent protection as we engage
in assisting manufacturers increase production" said William J. Gastle, CEO of
Microbix. The company's technology will be licensed to manufacturers on a
Annual global flu vaccine production capacity is currently about
350 million doses. The Microbix process, if adopted worldwide, would increase
that amount to at least 700 million doses.
VIRUSMAX(TM) can be implemented quickly and cost-effectively by
manufactures, allowing them to ramp up production in a matter of months.
Microbix has established a Special Workgroup for Applied Technology Transfer
(SWATT) to help manufacturers adopt the process. The SWATT team is now being
sent to various facilities to assist customers in implementing the technology
and training local personnel.
The World Health Organization, in its Global Vaccine Action Plan, noted
that if an influenza pandemic were to occur, the potential vaccine supply
would fall far short of the amount needed. Among all the strategies outlined
in the WHO's Action Plan, increased production yields was identified as "the
most direct mechanism to make more doses available."
Microbix specializes in developing proprietary biological technologies,
including biotherapeutic drugs, vaccine technologies and animal reproduction
technologies. It has been researching and developing the flu vaccine yield
enhancement technology for a number of years, with a team at the company's
Toronto laboratories spearheading these efforts.
This press release contains forward-looking statements, which are subject
to risks and uncertainties that could cause actual results to differ
materially from those set forth in the forward-looking statements such as the
risks associated with licensing the technology to vaccine manufacturers. These
forward-looking statements represent the Company's judgment as of the date of
this press release. The Company disclaims any intent or obligation to update
these forward-looking statements.
For further information:
For further information: visit www.microbix.com or contact: William J.
Gastle, CEO, Microbix Biosystems Inc., (416) 234-1624 x 230; James Long, CFO,
Microbix Biosystems Inc., (416) 234-1624 x265